拉米夫定治疗慢性乙型肝炎患者的疗效及其预测因素研究-study on the efficacy and predictors of lamivudine in the treatment of chronic hepatitis b.docxVIP

下载本文档

2
0
约2.82万字
约 32页
2018-05-29 发布于上海
举报
版权申诉

拉米夫定治疗慢性乙型肝炎患者的疗效及其预测因素研究-study on the efficacy and predictors of lamivudine in the treatment of chronic hepatitis b.docx

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

拉米夫定治疗慢性乙型肝炎患者的疗效及其预测因素研究-study on the efficacy and predictors of lamivudine in the treatment of chronic hepatitis b

安徽医科大学硕士学位论文安徽医科大学硕士学位论文 PAGE PAGE 6 ALT, HBV DNA , HBeAg status before treatment and the degree of decreasing log10 HBV DNA at week 4th ， univariate analysised the response among the groups, furthermore analysised age, gender, family history of hepatitis B among the groups. Results：There were 21 patients (21.3%) received complete response (CR),64 patients (71.1%) received partial response (PR) and 5 patients (5.6%) received non- response (NR) in 90 patients, and the rate of normalization of ALT was75.6％, the clearance of HBV DNA to undectable rate (＜1×103 copies/ml) was 85.6％; In 79 patients with HBeAg-positive, the rate of HBeAg loss and seroconversion were 29.6％and 9.9％, respectively ; In patients with baseline serum ALT≥2× upper limit of normal (ULN) , the rates of complete response (CR) ,virological response(VR) and serological response(SR) were higher than with baseline serum ALT≥2×ULN (P＜0.05); In patients with HBeAg-negative, the rates of CR and VR were higher than with HBeAg-positive (P＜0.05); The group of HBV DNA ＜8log10 compared with the group of HBV DNA≥8log10 had higher rates of SR (P＜0.05); The rates of VR in patients of age＜40 years were 72.1% and in patients of age≥40 years were 95.5% (P＜0.05); Gender and hepatitis B family history seem no effect with efficacy. During the therapy, in patients with HBV DNA＜1×103 copies/ml compared with patients with HBV DNA≥1×103 copies/ml at week 4. 12 and 24, the rate of normalization of ALT had no statistical diferences, in the group of HBV DNA＜1×103 copies/ml at week 4 and 24 , had high rates of the clearance of HBV DNA to undectable at week 48 (P＜0.05), in the group of HBV DNA＜1×103 copies/ml at week 4 and 12 , had high rates of SR at week 48 (P＜ 0.05), In patients with the degree of decreasing HBV DNA≥2 log10 at week 4, there were 12 patients(25.5％) received CR, 43 patients(91.5％) received VR, while there were no patients received CR. only 8 patients received VR in patients with the degre